Glucosamine Linked to Alzheimer's Risk

A recent study published in Nature Metabolism reveals a concerning association between the common supplement glucosamine and increased mortality risk for individuals with Alzheimer's disease. Patients taking glucosamine showed a 25% higher likelihood of death within five years compared to non-users. Furthermore, the supplement appeared to accelerate the progression of mild cognitive impairment to full Alzheimer's disease in 25% of cases.

Experiments conducted on mice engineered to exhibit Alzheimer's-like symptoms provided a potential mechanism. Blocking the enzyme responsible for sugar production improved dementia symptoms in these mice, whereas feeding them glucosamine exacerbated memory loss. Healthy mice, however, showed no adverse effects from the supplement.

The research, based on anonymized medical records from the University of Florida Health system, analyzed data from 24,000 dementia patients and 41,000 with mild cognitive impairment. While previous studies suggested glucosamine might benefit cognitively healthy adults, this new research indicates potential harm for those with existing cognitive decline.

It's important to note that the study identified an association, not direct causation, as a controlled human trial is needed. Future research aims to explore the dose-dependency, brand variations, and effects on other dementia types. Clinical trials are also planned to assess whether discontinuing glucosamine can slow cognitive decline.